JP7492917B2 - 抗白金化学保護剤を含む高張医薬組成物 - Google Patents

抗白金化学保護剤を含む高張医薬組成物 Download PDF

Info

Publication number
JP7492917B2
JP7492917B2 JP2020564795A JP2020564795A JP7492917B2 JP 7492917 B2 JP7492917 B2 JP 7492917B2 JP 2020564795 A JP2020564795 A JP 2020564795A JP 2020564795 A JP2020564795 A JP 2020564795A JP 7492917 B2 JP7492917 B2 JP 7492917B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hypertonic pharmaceutical
hypertonic
hyaluronan
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513558A (ja
JP2021513558A5 (enExample
Inventor
フー、チー－イン
リー、ジョン
シー、フシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decibel Therapeutics Inc
Original Assignee
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decibel Therapeutics Inc filed Critical Decibel Therapeutics Inc
Publication of JP2021513558A publication Critical patent/JP2021513558A/ja
Publication of JP2021513558A5 publication Critical patent/JP2021513558A5/ja
Priority to JP2024081711A priority Critical patent/JP2024098070A/ja
Application granted granted Critical
Publication of JP7492917B2 publication Critical patent/JP7492917B2/ja
Priority to JP2026077143A priority patent/JP2026119177A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2020564795A 2018-02-09 2019-02-08 抗白金化学保護剤を含む高張医薬組成物 Active JP7492917B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024081711A JP2024098070A (ja) 2018-02-09 2024-05-20 抗白金化学保護剤を含む高張医薬組成物
JP2026077143A JP2026119177A (ja) 2018-02-09 2026-05-01 抗白金化学保護剤を含む高張医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628824P 2018-02-09 2018-02-09
US62/628,824 2018-02-09
PCT/US2019/017334 WO2019157370A1 (en) 2018-02-09 2019-02-08 Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024081711A Division JP2024098070A (ja) 2018-02-09 2024-05-20 抗白金化学保護剤を含む高張医薬組成物

Publications (3)

Publication Number Publication Date
JP2021513558A JP2021513558A (ja) 2021-05-27
JP2021513558A5 JP2021513558A5 (enExample) 2022-02-15
JP7492917B2 true JP7492917B2 (ja) 2024-05-30

Family

ID=67549759

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020564795A Active JP7492917B2 (ja) 2018-02-09 2019-02-08 抗白金化学保護剤を含む高張医薬組成物
JP2024081711A Pending JP2024098070A (ja) 2018-02-09 2024-05-20 抗白金化学保護剤を含む高張医薬組成物
JP2026077143A Pending JP2026119177A (ja) 2018-02-09 2026-05-01 抗白金化学保護剤を含む高張医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024081711A Pending JP2024098070A (ja) 2018-02-09 2024-05-20 抗白金化学保護剤を含む高張医薬組成物
JP2026077143A Pending JP2026119177A (ja) 2018-02-09 2026-05-01 抗白金化学保護剤を含む高張医薬組成物

Country Status (12)

Country Link
US (5) US10709732B2 (enExample)
EP (1) EP3749309A4 (enExample)
JP (3) JP7492917B2 (enExample)
KR (1) KR102860981B1 (enExample)
CN (1) CN112020359A (enExample)
AU (1) AU2019218232B2 (enExample)
BR (1) BR112020016059A2 (enExample)
CA (1) CA3090783A1 (enExample)
IL (1) IL276569B2 (enExample)
MX (2) MX2020008323A (enExample)
SG (1) SG11202007595WA (enExample)
WO (1) WO2019157370A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039375A1 (en) 2016-08-23 2018-03-01 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
BR112020016059A2 (pt) 2018-02-09 2020-12-08 Decibel Therapeutics, Inc. Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
BR112021000021A2 (pt) * 2018-07-03 2021-03-30 Fennec Pharmaceuticals, Inc. Tiossulfato de sódio anidro e formulações do mesmo
US20220054640A1 (en) * 2018-12-11 2022-02-24 Decibel Therapeutics, Inc. Compositions and methods for the delivery of therapeutic agents across the round window membrane
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020256548A1 (en) * 2019-06-19 2020-12-24 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss
CN114845721A (zh) * 2019-10-30 2022-08-02 奥德纳米有限公司 用于药物诱导的耳毒性的耳用制剂
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
US20260027327A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Otic drug delivery system and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509982A (ja) 2005-09-28 2009-03-12 アウリス メディカル アクチエンゲゼルシャフト 内耳疾患を治療するための医薬品組成物
JP2012532824A (ja) 2009-07-08 2012-12-20 ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズ チオ硫酸ナトリウムを含有する薬学的組成物
JP2014513054A (ja) 2011-02-18 2014-05-29 オトノミ―，インク． 薬物により誘発される耳毒性の予防又は回復

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6497902B1 (en) 1999-12-01 2002-12-24 The Regents Of The University Of Michigan Ionically crosslinked hydrogels with adjustable gelation time
KR20030014208A (ko) 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 티올계 화학보호제 화합물의 투여
EP1404689A1 (en) * 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
US7790699B2 (en) 2004-10-12 2010-09-07 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
WO2008056822A1 (en) 2006-11-09 2008-05-15 Takeda Pharmaceutical Company Limited Pharmaceutical composition comprising a dihydrobenzofuranyl isoindoline and a lipophilic component
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US10130514B2 (en) 2011-09-26 2018-11-20 Incube Labs, Llc System and method for delivery of a therapeutic agent to the inner ear
FR2992861B1 (fr) * 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
JP7074663B6 (ja) * 2015-05-28 2022-08-01 ベイラー カレッジ オブ メディスン グルタチオンレベルを改善するためのｎ－アセチルシステイン及びグリシンの補給の効果
AU2016304585B2 (en) 2015-08-05 2023-04-06 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
US20190038756A1 (en) 2016-02-10 2019-02-07 Cocoon Biotech Inc. Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs, silk fibroin, and a gelling agent and uses thereof
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
EP3570826A4 (en) 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
US10596190B2 (en) 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
WO2019118330A1 (en) 2017-12-12 2019-06-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
US11918653B2 (en) 2017-12-22 2024-03-05 Dompé Farmaceutici S.P.A. Triglyceride otic formulations and uses thereof
US10946443B2 (en) 2018-01-08 2021-03-16 Hamilton Sundstrand Corporation Removal of unfused powder from an additive-manufactured part using piezoelectric transducers
WO2019140012A1 (en) 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
BR112020016059A2 (pt) 2018-02-09 2020-12-08 Decibel Therapeutics, Inc. Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina
US20210186943A1 (en) 2018-04-25 2021-06-24 Otonomy, Inc. Otic formulations for drug-induced ototoxicity
IT201800006566A1 (it) 2018-06-21 2019-12-21 Composizione per prevenire e trattare disordini uditivi e vestibolari
BR112021000021A2 (pt) 2018-07-03 2021-03-30 Fennec Pharmaceuticals, Inc. Tiossulfato de sódio anidro e formulações do mesmo
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020256548A1 (en) 2019-06-19 2020-12-24 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Sodium thiosulfate gel for preventing or reducing hearing loss

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509982A (ja) 2005-09-28 2009-03-12 アウリス メディカル アクチエンゲゼルシャフト 内耳疾患を治療するための医薬品組成物
JP2012532824A (ja) 2009-07-08 2012-12-20 ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズ チオ硫酸ナトリウムを含有する薬学的組成物
JP2014513054A (ja) 2011-02-18 2014-05-29 オトノミ―，インク． 薬物により誘発される耳毒性の予防又は回復

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
稲垣洋三，外４名，"内耳DDSに最適な薬物徐放効果を有するヒアルロン酸の検討"，Audiology Japan，2013年，Vol.56, No.5，p.473-474

Also Published As

Publication number Publication date
BR112020016059A2 (pt) 2020-12-08
SG11202007595WA (en) 2020-09-29
JP2026119177A (ja) 2026-07-16
EP3749309A1 (en) 2020-12-16
US20210308176A1 (en) 2021-10-07
CA3090783A1 (en) 2019-08-15
US20200338119A1 (en) 2020-10-29
MX2020008323A (es) 2020-10-14
US11857567B2 (en) 2024-01-02
MX2023001963A (es) 2023-02-23
WO2019157370A1 (en) 2019-08-15
US20240350533A1 (en) 2024-10-24
US11071751B2 (en) 2021-07-27
KR102860981B1 (ko) 2025-09-18
CN112020359A (zh) 2020-12-01
AU2019218232A1 (en) 2020-09-24
IL276569B2 (en) 2023-06-01
AU2019218232B2 (en) 2024-12-19
JP2024098070A (ja) 2024-07-19
IL276569A (en) 2020-09-30
US20250381219A1 (en) 2025-12-18
JP2021513558A (ja) 2021-05-27
US20190336524A1 (en) 2019-11-07
EP3749309A4 (en) 2021-12-08
US10709732B2 (en) 2020-07-14
KR20200129107A (ko) 2020-11-17

Similar Documents

Publication Publication Date Title
JP2024098070A (ja) 抗白金化学保護剤を含む高張医薬組成物
EP3294212B1 (en) Drug delivery from hydrogels
US20240226141A9 (en) Methods of otoprotection against platinum-based antineoplastic agents
JP2009509982A (ja) 内耳疾患を治療するための医薬品組成物
WO2011063606A1 (zh) 一种含加替沙星的眼用凝胶剂及其制备方法
JP7585240B2 (ja) 白金ベースの抗腫瘍剤に対する耳毒性保護のための医薬組成物
CN116211799B (zh) 一种局麻药复合物混悬剂
JP7049557B2 (ja) 生物組織の癒着の予防
CA3142153C (en) Methods of otoprotection against platinum-based antineoplastic agents
BR122023025163A2 (pt) Composições farmacêuticas hipertônicas contendo um agente quimioprotetor antiplatina, seu uso e seu método de preparação
KR102125256B1 (ko) 점안용 담체 복합체, 이를 포함하는 약학 조성물, 및 약학 조성물의 제조방법
US12233157B1 (en) Hydrogel formulations and methods and devices for administration of the same
JP2015209417A (ja) 経口疾患治療薬
WO2026024285A1 (en) Hydrogel formulations and methods and devices for administration of the same
HK40107641A (en) Composition and use of ropivacaine or its pharmaceutically acceptable salts
JP2003342166A (ja) 眼内疾患用製剤
KR20240080282A (ko) 두타스테리드를 포함하는 서방성 제제 및 그 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240520

R150 Certificate of patent or registration of utility model

Ref document number: 7492917

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150